Neuraptive Therapeutics said that it has enrolled the first patient in its phase 2a clinical trial of NTX-001 for the treatment and prevention of facial paralysis needing surgical repair.

The mid-stage facial paralysis prevention study will assess the safety and efficacy of NTX-001 in peripheral nerve injuries caused by trauma in comparison to the standard of care.

Evan Tzanis — Neuraptive Therapeutics EVP and R&D Head said: “We are pleased to enroll our first patient in this important Phase 2 study which will further our understanding of the potential role of NTX-001 in an area of significant unmet medical need.”

Topline results of the NTX-001 phase 2a clinical trial are expected to be released in the second half of next year.

Robert Radie — Chairman and CEO of Neuraptive Therapeutics said: “With the initiation of our Facial Paralysis Prevention study, and our recent progress in the Trauma study, we are positioned to have two significant readouts in our proof-of-concept studies within the next 18 months, which is a significant step forward in development towards understanding an approval pathway for NTX-001.

“These studies are a testament to Neuraptive’s commitment to finding innovative solutions to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves.”

In 2020, Neuraptive Therapeutics was given fast track designation from the US Food and Drug Administration (FDA) for NTX-001 in the treatment of peripheral nerve injuries.

  Evan Tzanis, facial paralysis, Neuraptive Therapeutics, NTX-001, Robert Radie, Trauma, USA